Assenagon Asset Management
PCVX icon

Assenagon Asset Management’s Vaxcyte PCVX Stock Holding History

Assenagon Asset Management’s Portfolio PCVX Stock Details PCVX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$5.9M Sell
101,433
-1,063,380
-91% -$57.8M 0.01% 626
2026
Q1 		$67.7M Buy
1,164,813
+620,085
+114% +$33.7M 0.1% 155
2025
Q4 		$25.1M Buy
544,728
+324,778
+148% +$14.5M 0.03% 328
2025
Q3 		$7.92M Buy
219,950
+171,974
+358% +$5.7M 0.01% 531
2025
Q2 		$1.56M Sell
47,976
-275,589
-85% -$9.03M ﹤0.01% 829
2025
Q1 		$12.2M Buy
+323,565
New +$25.9M 0.02% 393
2024
Q3 		– Sell
-2,826
Closed -$213K – 1447
2024
Q2 		$213K Buy
+2,826
New +$192K ﹤0.01% 1363

Other funds holding PCVX

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
JT
Jupiter Topco New York $245B AUM
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $11.5B AUM 168.77% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return

Assenagon Asset Management's PCVX Position: Q2 2026 in Review

Assenagon Asset Management reduced its Vaxcyte (PCVX) stake by 91% in Q2 2026, selling an estimated $57.8M and leaving 101,433 shares worth $5.9M. The position accounts for 0.01% of the portfolio, ranked #626.

Assenagon Asset Management first reported a position in PCVX in Q2 2024 and has held it in 7 quarters since. The position peaked at $67.7M in Q1 2026. 331 funds tracked by Wall St. Rank hold PCVX as of Q2 2026.

  • Assenagon Asset Management held 101,433 shares of Vaxcyte worth $5.9M as of Q2 2026.
  • Assenagon Asset Management sold 1,063,380 Vaxcyte shares in Q2 2026, an estimated $57.8M.
  • Vaxcyte made up 0.01% of Assenagon Asset Management's portfolio in Q2 2026, its #626 holding.
  • Assenagon Asset Management first reported a position in Vaxcyte in Q2 2024 and has held it in 7 quarters since.
  • Assenagon Asset Management's Vaxcyte position peaked at $67.7M in Q1 2026.
  • 331 funds tracked by Wall St. Rank held Vaxcyte as of Q2 2026.

Based on Assenagon Asset Management's 13F filing for Q2 2026, filed 8 Jul 2026.